🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the battle against superbug strains of the infection, according to health experts.

A Worldwide Health Concern

The sexually transmitted infection are escalating globally, with estimates suggesting in excess of 82 million new cases each year. Particularly high rates are reported in the African continent and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce therapeutic options currently available.”

Medical experts are increasingly worried about the rise in treatment-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, marketed under the name a brand name, was approved by the US Food and Drug Administration in December for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists believe that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GSK, gained clearance in concurrent days. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This approval represents a significant shift in the treatment of superbug gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Research Study Outcomes and Global Access

As per results published in a prominent scientific publication, the new drug eradicated the vast majority of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which uses an injection and a pill. The trial included nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the ability to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have shared hope. Access to a easy-to-administer therapy such as this is seen as a "revolutionary step" for managing the epidemic. This is deemed vital to reduce the burden of the infection for patients and to stop the proliferation of highly drug-resistant gonorrhoea globally.